publication date: Jan. 23, 2015

ASCO Teams with SAP For CancerLinQ Project


The American Society of Clinical Oncology announced Jan. 21 that its CancerLinQ health information technology project will use the SAP HANA platform.

SAP HANA is a flexible, in-memory data management and application platform that provides predictive text analytics, spatial processing and data virtualization. SAP has teamed with medical organizations in Germany and Japan for cancer data analytics and genomic analysis.

According to ASCO, CancerLinQ is one of the only major cancer data initiatives being developed and led by physicians with the primary purpose of improving patient care.

“In teaming with SAP, we found an ideal company with state-of-the-art technology, a commitment to invest major new resources, and a clear dedication to our patient care mission,” said ASCO President Peter Yu.

According to ASCO, CancerLinQ is expected to use patient care data from millions of electronic health records to provide feedback and clinical decision support to providers. Doctors should be able to receive personalized insights and help patients access care based on up-to-date findings.

Eight oncology practices around the U.S. have signed agreements with CancerLinQ to provide patient records for the first version of CancerLinQ, scheduled for release in late 2015. Seven more large cancer centers are expected to join the effort, meaning approximately 500,000 patients will be represented in CancerLinQ.

The eight oncology practices are: Inova Comprehensive Cancer & Research Institute; South Coast Centers for Cancer Care; New England Cancer Specialists; Medical Oncology Hematology Consultants; Cancer Treatment Centers of America; Marin Cancer Care; Space Coast Cancer Center; and Michiana Hematology-Oncology P.C.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.